BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- New data presented at ECCMID highlight the microbiological and pharmacokinetic profiles of Basilea’s (SWX:BSLN) two late-stage drug candidates ceftobiprole and isavuconazole. Studies reported both for ceftobiprole, the first anti-MRSA broad-spectrum cephalosporin in late-stage development, and for isavuconazole, a novel azole for the treatment of invasive fungal infections, yielded further data on their respective breadths of spectrum, and pharmacokinetic properties.
